Gen9 And SynbiCITE Announce Partnership To Accelerate Technology Commercialization Through Synthetic Biology

CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--Gen9, a leader in the development of scalable technologies for synthesizing and assembling DNA, and SynbiCITE, a pioneering Innovation and Knowledge Centre (IKC) dedicated to promoting adoption and usage of synthetic biology, today announced a partnership that provides members of the SynbiCITE research community access to Gen9’s high-throughput BioFab® platform for gene synthesis.

MORE ON THIS TOPIC